A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Publication of trial rationale/design

Starting at month 24, a publication is written and submitted to a cardiology journal, describing the rationale and design of the clinical trial; a second publication is written and submitted on month 60, describing the results of the trial.

Abstracts presentation at heart failure meetings

Starting at month 12, abstracts on the scope, design and implementation of the clinical trial are submitted for presentation at Heart Failure congresses

Short presentation of study results to general audience

A short oral presentation of the study results is made to general audience through media communication at the ESCHFA Spring meeting

Contact with patients' organisations through ad hoc initiative of HFA/ESC

Starting at month 24 contacts are established with patients organizations through ad hoc initiatives of the Heart Failure Association of the European Society of Cardiology every 2 years

Functional website

A public website for the trial is implemented and functional

Pubblicazioni

Overexpression of endothelial β 3 ‐adrenergic receptor induces diastolic dysfunction in rats

Autori: Justine Dhot, Marine Ferron, Valentine Prat, Antoine Persello, David Roul, David Stévant, Damien Guijarro, Nicolas Piriou, Virginie Aillerie, Angélique Erraud, Gilles Toumaniantz, Morteza Erfanian, Angela Tesse, Amandine Grabherr, Laurent Tesson, Séverine Menoret, Ignacio Anegon, Jean‐Noël Trochu, Marja Steenman, Michel De Waard, Bertrand Rozec, Benjamin Lauzier, Chantal Gauthier
Pubblicato in: ESC Heart Failure, Numero 7/6, 2020, Pagina/e 4159-4171, ISSN 2055-5822
Editore: ESC Heat failure
DOI: 10.1002/ehf2.13040

Early nebivolol treatment is beneficial in myocardial infarction in rats partly through β3‐adrenoceptor remodelling

Autori: Leslie Audigane, Antoine Persello, Nicolas Piriou, Marine Ferron, Jean‐Noël Trochu, Benjamin Lauzier, Chantal Gauthier, Bertrand Rozec
Pubblicato in: Clinical and Experimental Pharmacology and Physiology, Numero 48/7, 2021, Pagina/e 1007-1015, ISSN 0305-1870
Editore: Blackwell Publishing Inc.
DOI: 10.1111/1440-1681.13447

Beta 3 adrenoreceptors protect from hypertrophic remodelling through AMP‐activated protein kinase and autophagy

Autori: Emilie Dubois‐Deruy, Roselle Gelinas, Christophe Beauloye, Hrag Esfahani, Lauriane Y.M. Michel, Chantal Dessy, Luc Bertrand, Jean‐Luc Balligand
Pubblicato in: ESC Heart Failure, Numero 7/3, 2020, Pagina/e 920-932, ISSN 2055-5822
Editore: ESC heart failure
DOI: 10.1002/ehf2.12648

Phosphatase regulatory subunits in beta-adrenergic signalling: a delicate balancing act

Autori: Jean-Luc Balligand
Pubblicato in: Cardiovascular Research, Numero 115/3, 2018, Pagina/e 477-478, ISSN 0008-6363
Editore: Elsevier BV
DOI: 10.1093/cvr/cvy275

Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Be

Autori: Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, Oana Brosteanu, Dirk Hasenclever, Barbara Casadei, Frank Edelmann, Gerasimos Filippatos, Damien Gruson, Ignatios Ikonomidis, Renaud Lhommel, Masliza Mahmod, Stefan Neubauer, Alexandre Persu, Bernhard L. Gerber, Stefan Piechnik, Burkert Pieske, Elisabeth Pieske-Kraigher, Fausto Pinto, Piotr Ponikowski, Michele Senni, Jean-Noël Trochu, Nancy Van Ov
Pubblicato in: ESC Heart Failure, 2018, ISSN 2055-5822
Editore: ESC Heart Failure
DOI: 10.1002/ehf2.12306

β3-Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing cardiomyocytes

Autori: Sophie Schobesberger, Peter T Wright, Claire Poulet, Jose L Sanchez Alonso Mardones, Catherine Mansfield, Andreas Friebe, Sian E Harding, Jean-Luc Balligand, Viacheslav O Nikolaev, Julia Gorelik
Pubblicato in: eLife, Numero 9, 2020, ISSN 2050-084X
Editore: eLife Sciences Publications
DOI: 10.7554/elife.52221

Seminar: Leçon publique sur l'HFpEF

Autori: Anne-Catherine Pouleur
Pubblicato in: 2015
Editore: Anne-Catherine Pouleur

Youtube video

Autori: Nancy Van Overstraeten
Pubblicato in: 2015
Editore: Youtube

seminar

Autori: Jean-Luc Balligand
Pubblicato in: 2015
Editore: ESC

Vers un nouveau traitement de l'insuffisance cardiaque ?

Autori: Jean-Luc Balligand
Pubblicato in: 2015
Editore: UCL

Towards a new treatment for cardiac remodeling ?

Autori: Nancy Van Overstraeten
Pubblicato in: 2015
Editore: UCL IREC

A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease

Autori: EU
Pubblicato in: 2015
Editore: EU

Une molécule pour soulager le coeur

Autori: Frédéric Soumois
Pubblicato in: Le Soir, Numero daily, 2015
Editore: Le Soir

Piechnik Group: Myocardial functional T1 mapping – Advanced cardiac magnetic resonance imaging techniques

Autori: S. Piechnik
Pubblicato in: 2018
Editore: Radcliffe Department of Medicine

On-going EU Projects

Autori: ESC
Pubblicato in: 2016
Editore: ESC

New and Emerging Therapies and Targets: Beta-3 Agonists

Autori: Lauriane Y. M. Michel, Jean-Luc Balligand
Pubblicato in: 2016, Pagina/e 205-223
Editore: Springer International Publishing
DOI: 10.1007/164_2016_88

È in corso la ricerca di dati su OpenAIRE...

Risultati finali

Pubblicazioni

Condividi questa pagina

Scarica